As of 2025-07-03, the Intrinsic Value of Agios Pharmaceuticals Inc (AGIO) is 119.73 USD. This Agios valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 35.35 USD, the upside of Agios Pharmaceuticals Inc is 238.70%.
The range of the Intrinsic Value is 100.24 - 150.05 USD
Based on its market price of 35.35 USD and our intrinsic valuation, Agios Pharmaceuticals Inc (AGIO) is undervalued by 238.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 100.24 - 150.05 | 119.73 | 238.7% |
| DCF (Growth 10y) | 111.72 - 164.03 | 132.31 | 274.3% |
| DCF (EBITDA 5y) | 136.06 - 178.18 | 162.70 | 360.2% |
| DCF (EBITDA 10y) | 137.95 - 187.19 | 165.66 | 368.6% |
| Fair Value | 287.46 - 287.46 | 287.46 | 713.18% |
| P/E | 128.44 - 272.51 | 185.59 | 425.0% |
| EV/EBITDA | (80.92) - 178.53 | 32.56 | -7.9% |
| EPV | (49.22) - (66.73) | (57.97) | -264.0% |
| DDM - Stable | 49.60 - 102.72 | 76.16 | 115.4% |
| DDM - Multi | 41.47 - 72.71 | 53.32 | 50.8% |
| Market Cap (mil) | 2,047.47 |
| Beta | 1.73 |
| Outstanding shares (mil) | 57.92 |
| Enterprise Value (mil) | 1,968.51 |
| Market risk premium | 4.60% |
| Cost of Equity | 13.65% |
| Cost of Debt | 5.00% |
| WACC | 8.66% |